Regulation of endocrine-disrupting chemicals: Critical overview and deficiencies in toxicology and rsk assessment for human health

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 20, Issue 1, 2006, Pages 145-165

  Harvey, Philip W ^a   Everett, David J ^a  

^a UK   (United Kingdom)

Author keywords

Adrenal; Anti androgen; Antithyroid; Cancer; Cosmetics; Development; EDSTAC; Endocrine disruption; Hyperprolactinaemia; OECD; Oestrogen; Parabens; Pesticides; REACH; Siloxanes

Indexed keywords

4 HYDROXYBENZOIC ACID ESTER; COSMETIC; DEODORANT AGENT; ENDOCRINE DISRUPTOR; FOOD PRESERVATIVE; PESTICIDE; PROLACTIN; SILOXANE; SUNSCREEN;

BIOASSAY; BREAST CANCER; CHEMICAL ANALYSIS; CLINICAL PROTOCOL; DATA ANALYSIS; DISEASE ASSOCIATION; ENDOCRINE FUNCTION; ENDOCRINE FUNCTION TEST; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL PROTECTION; ESTROGEN ACTIVITY; FOOD SAFETY; HAZARD ASSESSMENT; HEALTH HAZARD; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOTION; MEDICAL RESEARCH; MOUSE; NONHUMAN; PATHOGENESIS; PUBLIC HEALTH SERVICE; RAT; REVIEW; RISK ASSESSMENT; SAFETY; TOXICOLOGY; TOXIN ANALYSIS;

ADULT; ANIMALS; CELL LINE; CELL LINE, TUMOR; COSMETICS; ENDOCRINE DISRUPTORS; EUROPEAN UNION; FEMALE; HUMANS; LEGISLATION, DRUG; MALE; MAXIMUM TOLERATED DOSE; RISK ASSESSMENT; TOXICITY TESTS; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

EID: 33644642967     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2005.09.008     Document Type: Review

References (88)

1. P.W. Harvey K.C. Rush A. Cockburn Endocrine and Hormonal Toxicology 1999 Wiley Chichester
2. S.C. Rastogi A. Schouten N. de Kruijf J.W. Weijland Contents of methyl-, ethyl-, propyl-, butyl- and benzylparaben in cosmetic products Contact Dermatitis 32 1995 28-30
3. S.C. Rastogi Analytical control of preservative labelling on skin creams Contact Dermatitis 43 2000 339-343
4. B. Gruvberger M. Bruze M. Tammela Preservatives in moisturisers on the Swedish market Acta Dermato-Venereologica 78 1998 52-56
5. J.A. Dodge Natural and anthropogenic environmental oestrogens: The scientific basis for risk assessment. Structure/ activity relationships Pure and Applied Chemistry 70 1998 1725-1733
6. H. Hong W. Tong H. Fang et al. Prediction of estrogen receptor binding for 58,000 chemicals using an integrated system of a tree based model with structural alerts Environmental Health Perspectives 110 2002 29-36
7. S.C. Gad Regulatory Toxicology 2nd edn 2001 Taylor and Francis London
8. A. Cockburn K.-H. Leist Current and regulatory trends in endocrine and hormonal toxicology P.W. Harvey K.C. Rush A. Cockburn Endocrine and Hormonal Toxicology 1999 Wiley Chichester 507-534
9. EDSTAC. Endocrine Disrupter Screening and Testing Advisory Committee (EDSTAC) Final Report, August 1998. United States Environmental Protection Agency. http://www.epa.gov/scipoly/oscpendo/history/ finalrpt.htm; 1998.
10. J. Ashby P.A. Lefevre The peripubertal male rat assay as an alternative to the Hershberger castrated male rat assay for the detection of anti-androgens, oestrogens and metabolic modulators Journal of Applied Toxicology 20 2000 35-47
11. J. Ashby Testing for endocrine disruption post-EDSTAC: Extrapolation of low dose rodent effects to humans Toxicology Letters 120 2001 233-242
12. P.T.C. Harrison Endocrine disrupters and human health. Current research will establish baseline indices British Medical Journal 323 2001 1317-1318
13. P.W. Harvey Parabens, oestrogenicity, underarm cosmetics and breast cancer: A perspective on a hypothesis Journal of Applied Toxicology 23 2003 285-288
14. P.W. Harvey P. Darbre Endocrine disrupters and human health: Could oestrogenic chemicals in body care cosmetics affect breast cancer incidence in women? A review of evidence and call for further research Journal of Applied Toxicology 24 2004 167-176
15. M. Sharpe D.S. Irvine How strong is the evidence of a link between environmental chemicals and adverse effects on human reproductive health? British Medical Journal 328 2004 447-451
16. USEPA. United States Environmental Protection Agency. Endocrine disruptor screening program: Early priority setting activities. http://www.epa.gov/scipoly/oscpendo/prioritysetting/activities.htm.
17. European Commission. Environment Directorate General. Endocrine Disrupters Website. http://europa.eu.int/comm/environment/endocrine/ strategy/substances_en.htm.
18. S. Wason G. Pohlmeyer-Esch C. Pallen et al. 17 alpha-methyltestosterone: 28 day oral toxicity study in the rat based on the 'Enhanced OECD Test Guideline 407' to detect endocrine effects Toxicology 192 2003 119-137
19. T. Kunimatsu T. Yamada K. Miyata et al. Evaluation for reliability and feasibility of the draft protocol for the enhanced rat 28-day subacute study (OECD Guideline 407) using androgen antagonist flutamide Toxicology 200 2004 77-89
20. P. Andrews A. Freyberger E. Hartmann et al. Sensitive detection of the endocrine effects of the estrogen analogue ethinylestradiol using a modified enhanced subacute rat study protocol (OECD Test Guideline no. 407) Archives of Toxicology 76 2002 194-202
21. P. Kennel C. Pallen E. Barale-Thomas et al. Tamoxifen: 28-day oral toxicity study in the rat based on the Enhanced OECD Test Guideline 407 to detect endocrine effects Archives of Toxicology 77 2003 487-499
22. K. Yamasaki Y. Tago K. Nagai et al. Comparison of toxicity studies based on the draft protocol for the 'Enhanced OECD test guideline no. 407' and the reasearch protocol 'Pubertal development and thyroid function in immature male rats' with 6-n-propyl-2-thiouracil Archives of Toxicology 76 2002 495-501
23. W. Mellert K. Deckardt J. Walter et al. Detection of endocrine-modulating effects of the antithyroid acting drug 6-propyl-2-thoiuracil in rats, based on the 'Enhanced OECD test guideline 407' Regulatory Toxicology and Pharmacology 38 2003 368-377
24. H.P. Gelbke M. Kayser A. Poole OECD test strategies and methods for endocrine disruptors Toxicology 205 2004 17-25
25. A. Worth M. Balls Alternative (non-animal) methods for chemical testing: current status and future prospects. A report prepared by ECVAM and the ECVAM working group on chemicals. Endocrine disruption in humans Alternatives to Laboratory Animals 30 supplement 1 2002 103-113 [chapter 11]
26. J. Dandrea R.D. Combes A survey of stakeholder organisations on the proposed new European chemical policy Alternatives to Laboratory Animals 31 2003 501-528
27. R.D. Combes Peer review of validation studies: An assessment of the role of the OECD by reference to the validation of the uterotrophic assay for endocrine disruptors Alternatives to Laboratory Animals 32 2004 111-117
28. P.W. Harvey D.J. Everett The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: Critical omissions from regulatory endocrine disrupter screening strategies for human health? Journal of Applied Toxicology 23 2003 81-87
29. R.D. Combes The case for taking account of metabolism when testing for potential endocrine disruptors in vitro ALTA 32 2004 121-135
30. P.W. Harvey I. Johnson Approaches to the assessment of toxicity data with endpoints related to endocrine disruption Journal of Applied Toxicology 22 2002 241-247
31. P.W. Harvey K.C. Rush A. Cockburn Endocrine and hormonal toxicology: An integrated mechanistic and target system approach P.W. Harvey K.C. Rush A. Cockburn Endocrine and Hormonal Toxicology 1999 Wiley Chichester 3-11
32. W.E. Ribelin The effects of drugs and chemicals upon the structure of the adrenal gland Fundamental Applied Toxicology 4 1984 105-119
33. P.W. Harvey The Adrenal in Toxicology: Target Organ and Modulator of Toxicity 1996 Taylor and Francis London
34. Raven PW, Hinson JP. Transport, action and metabolism of adrenal hormones and pathology and pharmacology of the adrenal gland. In: The Adrenal in Toxicology: Target Organ and Modulator of Toxicity. London: Taylor and Francis; 1996. p. 53-79.
35. C. Gopinath Comparative endocrine carcinogenesis P.W. Harvey K.C. Rush A. Cockburn Endocrine and Hormonal Toxicology 1999 Wiley Chichester 155-167
36. C.V. Clevenger P.A. Furth S.E. Hankinson L.A. Schuler The role of prolactin in mammary carcinoma Endocrine Reviews 24 2003 1-27
37. S.S. Tworoger A.H. Eliassen B. Rosner et al. Plasma prolactin concentrations and risk of postmenopausal breast cancer Cancer Research 64 2004 6814-6819
38. C.M. Perks A.J. Keith K.L. Goodhew et al. Prolactin acts as a potent survival factor for human breast cancer cell lines British Journal of Cancer 91 2004 305-311
39. J. Meng C.H. Tsai-Morris M.L. Dufau Human prolactin receptor variants in breast cancer: Low ratio of short forms to the long form human prolactin receptor associated with mammary carcinoma Cancer Research 64 2004 5677-5682
40. J.H. Gutzman D.E. Rugowski M.D. Schroeder et al. Multiple kinase cascades mediate prolactin signals to activate protein-1 in breast cancer cells Molecular Endocrinology 18 2004 3064-3075
41. USEPA. Determination of the appropriate FQPA safety factors for use in the tolerance setting process. Office of Pesticide Programs, Office of Prevention, Pesticides and Toxic Substances. http://www.epa.gov/oppfead1/ trac/science/#10_fold; 2002.
42. C.A. Kimmel M.D. King S.L. Makris Risk assessment perspectives for developmental immunotoxicology S.D. Holladay Developmental Immunotoxicology 2005 CRC Press Boca Raton 45-63
43. S.D. Holladay Developmental Immunotoxicology 2005 CRC Press Boca Raton
44. J.C. Philip C.D. John G.E. Gillies J.C. Buckingham Neuroendocrine and pituitary toxicology: Targets for drug action and potential consequences on immune function P.W. Harvey K.C. Rush A. Cockburn Endocrine and Hormonal Toxicology 1999 Wiley Chichester 171-208
45. E. Spinedi N.B. Perez R.C. Gaillard Neuroendocrine-immune interaction: impact of gender, negative energetic balance condition, and developmental stage on the mechanisms of the acute phase response of the inflammatory process in mammals S.D. Holladay Developmental Immunotoxicology 2005 CRC Press Boca Raton 303-353
46. A. Munck P.M. Guyre N.J. Holbrook Physiological functions of glucocorticoids in stress and their relation to pharmacological actions Endocrine Reviews 5 1984 25-44
47. Johnson I, Harvey PW. Study on the scientific evaluation of 12 substances in the context of endocrine disrupter priority list of actions. Report for the European Commission, Environment Directorate General, 2002, 613 pp. Available at http://europa.eu.int/comm/ environment/endocrine/documents/wrc_report.pdf; 2002.
48. E.J. Routledge J. Parker J. Odum et al. Some alkyl hydroxy benzoate preservatives (parabens) are estrogenic Toxicology and Applied Pharmacology 153 1998 12-19
49. J.R. Byford L.E. Shaw M.G. Drew et al. Oestrogenic activity of parabens in MCF7 human breast cancer cells The Journal of Steroid Biochemistry and Molecular Biology 80 2002 49-60
50. C. Lemini R. Jaimez M.E. Avila et al. In vivo and in vitro estrogen bioactivities of alkyl parabens Toxicology and Industrial Health 19 2003 69-79
51. A. Hossaini J.J. Larsen J.C. Larsen Lack of oestrogenic effects of food preservatives (parabens) in uterotrophic assays Food and Chemical Toxicology 38 2000 319-323
52. S. Oishi Lack of spermatotoxic effects of methyl and ethyl esters of p-hydroxybenzoic acid in rats Food and Chemical Toxicology 42 2004 1845-1849
53. T. Okubo Y. Yokoyama K. Kano I. Kano ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ER alpha and PR Food and Chemical Toxicology 39 2001 1225-1232
54. S. Oishi Effects of propylparaben on the male reproductive system Food and Chemical Toxicology 40 2002 1807-1813
55. G.P. Daston Developmental toxicity evaluation of butylparaben in Sprague-Dawley rats Birth Defects Research Part B Developmental and Reproductive Toxicology 71 2004 296-302
56. S. Oishi Effects of butylparaben on the male reproductive system in rats Toxicology and Industrial Health 17 2001 31-39
57. S. Oishi Effects of butylparaben on the male reproductive system in mice Archives of Toxicology 76 2002 423-429
58. 1 offspring maternally exposed to butyl p-hydroxybenzoic acid (butyl paraben) The Journal of Veterinary Medical Science 64 2002 227-235
59. P.D. Darbre J.R. Byford L.E. Shaw et al. Oestrogenic activity of isobutylparaben in vitro and in vivo Journal of Applied Toxicology 22 2002 219-226
60. P.D. Darbre J.R. Byford L.E. Shaw et al. Oestrogenic activity of benzylparaben Journal of Applied Toxicology 23 2003 43-51
61. C. Lemini G. Silva C. Timossi et al. Estrogenic effects of p-hydroxybenzoic acid in CD1 mice Environmental Research 75 1997 130-134
62. H. Bando S. Mohri F. Yamashita et al. Effects of skin metabolism on percutaneous penetration of lipophilic drugs Journal of Pharmaceutical Sciences 86 1997 759-761
63. P.D. Darbre A. Aljarrah W.R. Miller et al. Concentrations of parabens in human breast tumours Journal of Applied Toxicology 24 2004 5-13
64. P.W. Harvey D.J. Everett Significance of the detection of esters of p-hydroxybenzoic acid (parabens) in human breast tumours Journal of Applied Toxicology 24 2004 1-4
65. R. Clarke F. Leonessa J.N. Welch T.C. Skaar Cellular and molecular pharmacology of antiestrogen action and resistance Pharmacological Reviews 53 2001 25-72
66. SCF. Statement of the Scientific Committee on Food on the Parabens. European Commission, Health and Consumer Protection Directorate, Scientific Committee on Food SCF/CS/ADD/CONS/53 Final 2 April 2003. http://europa.eu.int/comm/food/fs/sc/scf; 2003.
67. L. Willis Final report on the safety assessment of isobutylparaben and isopropylparaben Journal of the American College of Toxicology 14 1995 364-372
68. K.G. McGrath An earlier age of breast cancer diagnosis related to more frequent use of antiperspirants/deodorants and underarm shaving European Journal of Cancer Prevention 12 2003 479-485
69. D.K. Mirick S. Davis D.B. Thomas Antiperspirant use and the risk of breast cancer Journal of the National Cancer Institute 94 20 2002 1578-1580
70. A. Bradford-Hill The environment and disease: Association or causation Proceedings of the Royal Society of Medicine 58 1966 295
71. H.M.D. Luu J.C. Hutter Bioavailability of octamethylcyclotetrasiloxane (D4) after exposure to silicones by inhalation and implantation Environmental Health Perspectives 109 2001 1095-1101
72. G. Zareba R. Galein P.E. Morrow M.J. Utell Percutaneous absorption studies of octamethylcyclotetrasiloxane using the human skin/nude mouse model Skin Pharmacology and Applied Skin Physiology 15 2002 184-194
73. S.V. Kala E.D. Lykissa M.W. Neely M.W. Lieberman Low molecular weight silicones are widely distributed after a single subcutaneous injection in mice The American Journal of Pathology 152 1998 645-649
74. B. He S. Rhodes-Brower M.R. Miller et al. Octamethylcyclotetrasiloxane exhibits estrogenic activity in mice via ER alpha Toxicology and Applied Pharmacology 192 2003 254-261
75. J.M. McKim P.C. Wilga W.J. Breslin et al. Potential estrogenic and antiestrogenic activity of the cyclic siloxane octamethylcyclotetrasiloxane (D4) and the linear siloxane hexamethyldisiloxane (HMDS) in immature rats using the uterotrophic assay Toxicological Sciences 63 2001 37-46
76. P.D. Darbre Underarm cosmetics are a cause of breast cancer European Journal of Cancer Prevention 10 2001 389-393
77. P.D. Darbre Underarm cosmetics and breast cancer Journal of Applied Toxicology 23 2003 89-95
78. EFSA Opinion of the scientific panel on food additives, flavouring, processing aids and materials in contact with food on a request from the commission related to para hydroxybenzoates (E 214-219). Question number EFSA-Q-2004-063. The EFSA Journal 83 2004 1-26
79. P.F. Ricci L.A. Cox T.R. MacDonald Precautionary principles: A jurisdiction-free framework for decision making under risk Human Experimental Toxicology 23 2004 579-600
80. L.M. Ellman C.R. Sunstein Hormesis, the precautionary principle and legal regulation Human Experimental Toxicology 23 2004 601-611
81. T. Hofer I. Gerner U. Gundert-Remy et al. Animal testing and alternative approaches for the human health risk assessment under the proposed new European regulation Archives of Toxicology 78 2004 549-564
82. R.M. Sharpe N.E. Skakkebaek Are oestrogens involved in falling sperm counts and disorders of the male reproductive tract? Lancet 341 1993 1392-1395
83. V. Beral Million women study collaborators. Breast cancer and hormone replacement in the million women study Lancet 362 2003 419-427
84. D.L. Ellsworth R.E. Ellswoth B. Love et al. Outer breast quadrants demonstrate increased levels of genomic instability Annals of Surgical Oncology 11 2004 861-868
85. D.L. Ellsworth R.E. Ellsworth M.N. Liebman et al. Genomic instability in histologically normal breast tissues: Implications for carcinogenesis Lancet Oncology 5 2004 753-758
86. P.W. Harvey Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: Prolactin involvement in human breast cancer and significance for toxicology risk assessments Journal of Applied Toxicology 25 2005 179-183
87. P.D. Gikas L. Mansfield K. Mokbel Do underarm cosmetics cause breast cancer? International Journal of Fertility 49 2004 212-214
88. L.J. Loretz A.M. Api L.M. Barraj et al. Exposure data for cosmetic products: Lipstick, body lotion, and face cream Food and Chemical Toxicology 43 2005 279-291